Alnylam Pharmaceuticals, Inc. (ALNY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY)

ALNY 434.07

-4.8%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	7/28/2006 12:40:50 PM
	of 166

don't agree and no current position but fwiw from zacks.. Alnylam Pharmaceuticals, Inc. (ALNY-NSDQ) Current Recommendation Sell Prior Recommendation Hold Date of Last Change 06/14/2006 Current Price (07/25/06) $12.60 Six- Month Target Price $9.50 OUTLOOK SUMMARY DATA Risk Level N/A Type of Stock Small-Blend Industry Med-Biomed/Gene Zacks Rank in Industry 28 of 149 Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi technology. The company possesses a deep, but very early-stage therapeutic pipeline. Therapeutic candidates developed using RNAi may offer some advantages over more traditional small molecule or protein-based drugs. But it s too early to judge the value of this technology. Clinical stage work is necessary to validate this technology. Alnylam s shares have gained 94% in the past 12 months, and are overvalued at current level compared to its peers. Therefore, we rate the shares Sell with a target price $9.50.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next